About US
Contact us
-
EMA panel issues positive opinion for DSP and Takeda's schizophrenia drug lurasidoneJapanese firms Dainippon Sumitomo Pharma (DSP) and Takeda Pharmaceutical (Takeda) have received positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human U2014/1/29
-
Apricus gets national phase approval in Belgium for erectile dysfunction cream VitarosUS-based pharmaceutical firm Apricus Biosciences has received national phase approval from Belgium's Ministry of Social Affairs, Public Health and Environment for Vitaros, indicated for the treatment2014/1/29
-
FDA Prohibits Ranbaxy’s Toansa, India Facility from Producing and Distributing Drugs for the US MarketFDA hasnotified Ranbaxy Laboratories, Ltd, that it is prohibited from manufacturing and distributing APIs from its facility in Toansa, India, for FDA-regulated drug products. The Toansa facility is no2014/1/28
-
AstraZeneca and Bristol-Myers Squibb announce EU approval for diabetes drug XigduoThe European Commission has granted marketing authorisation to AstraZeneca and Bristol-Myers Squibb's (BMS's) Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1,000mg tablets) fo2014/1/28
-
FDA grants orphan drug status to BioLineRx's BL-8040 for stem cell mobilisation treatmentIsrael-based clinical-stage biopharmaceutical firm BioLineRx has received notice from the US Food & Drug Administration (FDA) confirming an Orphan Drug Designation for BL-8040 as a treatment for s2014/1/27
-
MIP Technologies AB Presents a New Range of Polymeric Separation Resins for Industrial UseMIP Technologies (a subsidiary of Biotage AB), a leading global supplier of solutions and technologies for specialty polymeric separation materials, is pleased to present a new range of RENSA industri2014/1/27
-
Bayer launches takeover offer for all shares of Algeta for €2.1bnBayer Nordic's subsidiary Aviator Acquisition has started the voluntary cash offer to acquire all the shares of Norwegian oncology firm Algeta for Nkr362 per share. The total value of the transaction2014/1/24
-
UK research institutions and Nuevolution collaborate on cancer drug discoveryUK's Institute of Cancer Research (ICR) and Cancer Research Technology (CRT) have entered into a drug discovery collaboration with Denmark-based Nuevolution to identify novel lead candidates for treat2014/1/24
-
Santhera's Raxone gets French temporary approval for treatment of Leber's hereditary optic neuropathySwitzerland-based Santhera Pharmaceuticals has received 'Autorisation Temporaire d'Utilisation dite de cohorte' (cohort ATU), a temporary authorisation, from the French National Agency for Medicines a2014/1/23
-
Bladder Cancer Market to Witness Moderate Growth by 2017, Despite Anticipate​d Launch of EOquinThe bladder cancer therapeutics market in the six major countries (6MM) — the US, France, Germany, Italy, Spain and UK — is forecast to climb from $239.3 million in 2012 to $297.5 million by 2017, at2014/1/23